Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib Malate in Persistent or Recurrent Clear Cell Ovarian Carcinoma
NCT00979992Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2010
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in ovarian clear cell carcinoma (OCCC), sponsored by National Cancer Institute. Primary endpoints: Objective Tumor Response Rate up to 5 years and Percentage of Patients Who Survive Progression Free for at Least 6 Months. Started Apr 2010; status: completed.
02
Drugs
sunitinib
03
Conditions
ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT00979992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00979992.